<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Respiratory muscle weakness due to neuromuscular disease: Management
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Respiratory muscle weakness due to neuromuscular disease: Management
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Respiratory muscle weakness due to neuromuscular disease: Management
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Author:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Scott K Epstein, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Jeremy M Shefner, MD, PhD
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            R Sean Morrison, MD
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Renee D Stapleton, MD, PhD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Geraldine Finlay, MD
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Jul 24, 2023.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H1">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Respiratory muscle weakness due to neuromuscular disease can lead to acute and/or chronic ventilatory failure as well as recurrent aspiration and pneumonia. Management, which is largely supportive, can provide symptomatic relief, improve quality of life, and in some instances, prolong life.
        </p>
        <p>
         The management of respiratory muscle weakness due to neuromuscular disease will be reviewed here. The clinical manifestations and evaluation of patients with respiratory muscle weakness are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/5121.html" rel="external">
          "Respiratory muscle weakness due to neuromuscular disease: Clinical manifestations and evaluation"
         </a>
         .)
        </p>
        <p>
         The approach outlined in this topic is in keeping for the most-part with guidelines [
         <a href="#rid1">
          1
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H1761105625">
         <span class="h1">
          TREATMENT OF THE UNDERLYING DISORDER
         </span>
         <span class="headingEndMark">
          —
         </span>
         Respiratory muscle weakness is common among patients who have several types of neuromuscular disorders  (
         <a class="graphic graphic_table graphicRef69167" href="/z/d/graphic/69167.html" rel="external">
          table 1
         </a>
         ) [
         <a href="#rid2">
          2,3
         </a>
         ]. In all cases, treatment of the underlying neuromuscular disorder is indicated, if feasible.
        </p>
        <p>
         The response of respiratory muscle weakness to specific treatments may vary depending on the specific disease entity. For example, respiratory failure due to conditions such as Guillain-Barré syndrome, myasthenia gravis, polymyositis, and multiple sclerosis may be responsive to disease-specific therapy such that respiratory failure resolves as the underlying disease improves in response to therapy; in such cases ventilatory assistance may only be temporary. In contrast, other neuromuscular disorders are not reversible or may progress despite therapy (eg, amyotrophic lateral sclerosis [ALS], Duchenne muscular dystrophy [DMD]), thereby necessitating full-time ventilatory support and adjunctive aids. (See
         <a class="local">
          'Chronic ventilatory support'
         </a>
         below.)
        </p>
        <p>
         Specific treatments are found in individual topics:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         ALS (see
         <a class="medical medical_review" href="/z/d/html/5128.html" rel="external">
          "Disease-modifying treatment of amyotrophic lateral sclerosis"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/5129.html" rel="external">
          "Symptom-based management of amyotrophic lateral sclerosis"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Myasthenia gravis (see
         <a class="medical medical_review" href="/z/d/html/5157.html" rel="external">
          "Overview of the treatment of myasthenia gravis"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/5125.html" rel="external">
          "Myasthenic crisis"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Guillain-Barré syndrome (see
         <a class="medical medical_review" href="/z/d/html/5172.html" rel="external">
          "Guillain-Barré syndrome in adults: Treatment and prognosis"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Multiple sclerosis (see
         <a class="medical medical_review" href="/z/d/html/1687.html" rel="external">
          "Initial disease-modifying therapy for relapsing-remitting multiple sclerosis in adults"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/1698.html" rel="external">
          "Treatment of acute exacerbations of multiple sclerosis in adults"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/1690.html" rel="external">
          "Symptom management of multiple sclerosis in adults"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         DMD (see
         <a class="medical medical_review" href="/z/d/html/6181.html" rel="external">
          "Duchenne and Becker muscular dystrophy: Management and prognosis"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Polymyositis (see
         <a class="medical medical_review" href="/z/d/html/5160.html" rel="external">
          "Initial treatment of dermatomyositis and polymyositis in adults"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Diaphragmatic or phrenic nerve injury (see
         <a class="medical medical_review" href="/z/d/html/15134.html" rel="external">
          "Surgical treatment of phrenic nerve injury"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/15146.html" rel="external">
          "Recognition and management of diaphragmatic injury in adults"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Myotonic dystrophy (see
         <a class="medical medical_review" href="/z/d/html/5140.html" rel="external">
          "Myotonic dystrophy: Treatment and prognosis"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Mitochondrial myopathy (see
         <a class="medical medical_review" href="/z/d/html/5149.html" rel="external">
          "Mitochondrial disorders: Treatment"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H927164449">
         <span class="h1">
          ACUTE VENTILATORY SUPPORT
         </span>
        </p>
        <p class="headingAnchor" id="H2245979480">
         <span class="h2">
          Initial assessment
         </span>
         <span class="headingEndMark">
          —
         </span>
         Patients with respiratory muscle weakness may present with acute respiratory failure due to their underlying neuromuscular disease itself (eg, Guillain-Barré syndrome), a complication of their disease (eg, aspiration pneumonia), or another intercurrent illness (eg, acute congestive heart failure).
        </p>
        <p>
         Patients typically present with dyspnea and cough. Patients may also complain of a sense of "suffocation." Respiratory distress may not be as apparent as in patients who do not have respiratory muscle weakness. This is because many patients cannot increase their respiratory rate or tidal volume to meet ventilatory demand and additionally may not be able to expectorate large volumes of sputum, particularly if they are dehydrated. These features may mislead the clinician into believing that the patient is comfortable and does not need intubation. Thus, clinicians should look for subtle signs, such as thoracoabdominal paradox, and have a low threshold to perform arterial blood gas analysis for the early detection of acute hypercapnia.
        </p>
        <p>
         The need for noninvasive versus invasive ventilation should be evaluated. Indications for either form of ventilation in the acute setting are similar to those in the general population and are discussed separately. Aspects that are particular to patients with respiratory muscle weakness are discussed in this section. (See
         <a class="medical medical_review" href="/z/d/html/292.html" rel="external">
          "Approach to the adult with dyspnea in the emergency department"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/1458.html" rel="external">
          "The evaluation, diagnosis, and treatment of the adult patient with acute hypercapnic respiratory failure"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/1636.html" rel="external">
          "Noninvasive ventilation in adults with acute respiratory failure: Benefits and contraindications"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/268.html" rel="external">
          "The decision to intubate"
         </a>
         .)
        </p>
        <p>
         A surrogate marker of lung function has been studied as a tool to help clinicians decide who to intubate. As an example, a single breath count test (SBC) is performed by the patient taking full inhalation and then counting, for as long as possible, at a rate of two counts per second. Studies have shown a correlation between SBC testing and vital capacity with lower counts indicating more severe respiratory dysfunction. In a study of 68 Guillain-Barré patients admitted to neurocritical care unit, 75 percent with SBC &lt;19 required mechanical ventilation. A strong correlation between SBC and vital capacity was found [
         <a href="#rid4">
          4
         </a>
         ]. In a study of 94 patients with Guillain-Barré Syndrome, 32 of 44 patients with a single breath count &lt;7 required intubation compared to 0 of 50 patients with counts &gt;7 [
         <a href="#rid5">
          5
         </a>
         ]. Studies in patients with myasthenia gravis suggest that counts below 20 to 25 indicate abnormal respiratory function [
         <a href="#rid6">
          6
         </a>
         ]. Studies specifically examining the role of SBC in predicting the need for noninvasive ventilation (NIV) are not yet available. Nevertheless, it seems reasonable to consider NIV in acute settings when the SBC is &lt;20. There are insufficient data to make a recommendation in patients with stable chronic disease.
        </p>
        <p class="headingAnchor" id="H877363136">
         <span class="h2">
          Noninvasive ventilation
         </span>
         <span class="headingEndMark">
          —
         </span>
         The indications, contraindications  (
         <a class="graphic graphic_table graphicRef60442" href="/z/d/graphic/60442.html" rel="external">
          table 2
         </a>
         ), and technical aspects of initiating NIV  (
         <a class="graphic graphic_table graphicRef51201" href="/z/d/graphic/51201.html" rel="external">
          table 3
         </a>
         ) in patients with acute respiratory failure from respiratory muscle weakness, are similar to those in patients without respiratory muscle weakness. (See
         <a class="medical medical_review" href="/z/d/html/1636.html" rel="external">
          "Noninvasive ventilation in adults with acute respiratory failure: Benefits and contraindications"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/126295.html" rel="external">
          "Noninvasive ventilation in adults with acute respiratory failure: Practical aspects of initiation"
         </a>
         .)
        </p>
        <p>
         In brief, we suggest the following as a guide:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         We consider most patients with neuromuscular weakness and acute respiratory failure as candidates for NIV unless contraindications such as the need for immediate intubation or severe bulbar dysfunction are present  (
         <a class="graphic graphic_table graphicRef60442" href="/z/d/graphic/60442.html" rel="external">
          table 2
         </a>
         ). Patients with significant bulbar dysfunction are poor candidates for NIV since they are unable to protect their lower airway and are at high risk of aspiration with NIV.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In general, we initiate NIV using an oronasal mask to minimize leaks and ensure adequate ventilation. Bilevel positive airway pressure (BPAP) is the most common mode used. BPAP requires inspiratory and expiratory PAP (IPAP, EPAP) to be set with the difference between the two representing the degree of pressure support. The bigger the difference the greater the tidal volume that is delivered. We make sure that patients are not overventilated relative to their baseline gas exchange parameters and target baseline values for arterial oxygen and carbon dioxide parameters.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Patients with respiratory muscle weakness (regardless of whether bulbar dysfunction is present) may experience upper airway obstruction with NIV. IPAP delivered via an oronasal mask may cause intermittent posterior displacement of the tongue resulting in inspiratory narrowing of the upper airway. An adequate EPAP level can help prevent this, especially if pharyngeal collapse caused by the abrupt reduction from inspiratory to expiratory pressure contributes to upper airway obstruction. Alternatively, the patient can be switched to a nasal mask with a chin strap (to prevent air leak from the mouth) [
         <a href="#rid7">
          7
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         For patients already on chronic NIV due to chronic respiratory failure from respiratory muscle weakness, settings and duration of use may need to be increased to accommodate increased ventilatory needs. For example, the IPAP may need to be increased to increase the tidal volume delivered and the support may need to be extended from nocturnal support only to 24 hour support.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         For patients with upper extremity weakness, there is a relative contraindication to NIV since they cannot grasp the mask to remove it if needed (eg, in the event of unexpected vomiting).
        </p>
        <p>
        </p>
        <p>
         In patients with acute respiratory failure from respiratory muscle weakness, small observational studies suggest that NIV may decrease the need for invasive mechanical ventilation, shorten intensive care unit (ICU) length of stay, and improve mortality [
         <a href="#rid8">
          8-10
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In a prospective cohort study of 17 patients with neuromuscular disease who received NIV for acute respiratory failure (24 episodes), 79 percent did not progress to invasive mechanical ventilation [
         <a href="#rid9">
          9
         </a>
         ]. A smaller retrospective study demonstrated similar findings [
         <a href="#rid10">
          10
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         An observational study compared 14 patients with neuromuscular disease who received NIV for acute respiratory failure to 14 historical controls who received invasive mechanical ventilation [
         <a href="#rid8">
          8
         </a>
         ]. The NIV group had lower mortality, a shorter length of ICU stay, and lower need for invasive mechanical ventilation. However, half of those on NIV also received a percutaneously placed small-bore tube providing tracheal access for secretion removal (ie, "mini-tracheostomy").
        </p>
        <p>
        </p>
        <p>
         Select features in patients with acute respiratory failure from respiratory muscle weakness may predict the need for NIV. In a study of 32 patients with amyotrophic lateral sclerosis (ALS) who had acute respiratory infection, predictors of the need for NIV included a forced vital capacity (FVC) &lt;55 percent predicted and a reduced peak cough flow &lt;2.9 L/sec [
         <a href="#rid11">
          11
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/5121.html" rel="external">
          "Respiratory muscle weakness due to neuromuscular disease: Clinical manifestations and evaluation", section on 'Diagnostic evaluation'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1908650114">
         <span class="h2">
          Invasive mechanical ventilation
         </span>
        </p>
        <p class="headingAnchor" id="H1928610847">
         <span class="h3">
          Indications
         </span>
         <span class="headingEndMark">
          —
         </span>
         Patients who need immediate invasive mechanical ventilation include those who present with cardiorespiratory arrest, severe respiratory distress, marked blood gas abnormalities, or impaired consciousness, and patients who have contraindications to NIV (eg, severe bulbar dysfunction with aspiration)  (
         <a class="graphic graphic_table graphicRef60442" href="/z/d/graphic/60442.html" rel="external">
          table 2
         </a>
         ). Invasive mechanical ventilation should be initiated “early” (ie, before it is needed emergently), especially in patients with acutely progressive neuromuscular weakness, since early intubation may decrease the risk of early-onset pneumonia [
         <a href="#rid12">
          12
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/268.html" rel="external">
          "The decision to intubate"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/1458.html" rel="external">
          "The evaluation, diagnosis, and treatment of the adult patient with acute hypercapnic respiratory failure"
         </a>
         .)
        </p>
        <p>
         Intubation with select induction agents should be considered. Agents including
         <a class="drug drug_general" data-topicid="8588" href="/z/d/drug information/8588.html" rel="external">
          ketamine
         </a>
         ,
         <a class="drug drug_general" data-topicid="8428" href="/z/d/drug information/8428.html" rel="external">
          etomidate
         </a>
         , combined ketamine with
         <a class="drug drug_general" data-topicid="9826" href="/z/d/drug information/9826.html" rel="external">
          propofol
         </a>
         , or reduced dose propofol may be preferred since they may decrease the risk of prolonged hypotension that frequently follows intubation in patients with neuromuscular weakness who are hypovolemic and debilitated. Patients with dysautonomia (especially with Guillain-Barré syndrome) may also experience profound hypotension if the patient is positioned head up or have a pronounced vagal response to intubation, especially if the dose of induction agent is inadequate.
         <a class="drug drug_general" data-topicid="9952" href="/z/d/drug information/9952.html" rel="external">
          Succinylcholine
         </a>
         should be avoided since it can trigger malignant hyperthermia in patients with some conditions that cause muscle weakness  (
         <a class="graphic graphic_table graphicRef65645" href="/z/d/graphic/65645.html" rel="external">
          table 4
         </a>
         ), life threatening hyperkalemia in patients with denervating conditions, anesthesia-induced rhabdomyolysis (eg, in patients with Duchenne or Becker muscular dystrophy), and result in an unpredictable response in patients with select muscle disorders (eg, patients with myasthenia are typically resistant to succinylcholine). Similarly, the response to nondepolarizing neuromuscular blocking agents (NMBAs; eg,
         <a class="drug drug_general" data-topicid="9872" href="/z/d/drug information/9872.html" rel="external">
          rocuronium
         </a>
         ,
         <a class="drug drug_general" data-topicid="10041" href="/z/d/drug information/10041.html" rel="external">
          vecuronium
         </a>
         ,
         <a class="drug drug_general" data-topicid="9270" href="/z/d/drug information/9270.html" rel="external">
          cisatracurium
         </a>
         ) is unpredictable in patients with some muscle diseases (eg, multiple sclerosis, amyotrophic lateral sclerosis) while patients with myasthenia gravis are exquisitely sensitive to nondepolarizing NMBAs. (See
         <a class="medical medical_review" href="/z/d/html/270.html" rel="external">
          "Rapid sequence intubation in adults for emergency medicine and critical care"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H267818495">
         <span class="h3">
          General ICU supportive measures
         </span>
         <span class="headingEndMark">
          —
         </span>
         Several supportive measures that are typically used during the care of mechanically ventilated patients are similar to those used in all critically ill patients. These issues are discussed separately:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Ventilator care (see
         <a class="medical medical_review" href="/z/d/html/1640.html" rel="external">
          "Overview of initiating invasive mechanical ventilation in adults in the intensive care unit"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Sedation and analgesia (see
         <a class="medical medical_review" href="/z/d/html/1606.html" rel="external">
          "Sedative-analgesia in ventilated adults: Management strategies, agent selection, monitoring, and withdrawal"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Venous thromboembolism prophylaxis (see
         <a class="medical medical_review" href="/z/d/html/1339.html" rel="external">
          "Prevention of venous thromboembolic disease in adult nonorthopedic surgical patients"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Stress ulcer prophylaxis (see
         <a class="medical medical_review" href="/z/d/html/1611.html" rel="external">
          "Stress ulcers in the intensive care unit: Diagnosis, management, and prevention"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Prevention of ventilator-associated pneumonia (see
         <a class="medical medical_review" href="/z/d/html/6995.html" rel="external">
          "Risk factors and prevention of hospital-acquired and ventilator-associated pneumonia in adults"
         </a>
         )
        </p>
        <p>
        </p>
        <p>
         Specific issues in managing ventilated patients with neuromuscular disorders include the following:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Avoidance of overventilation – We make sure that patients are not overventilated relative to their baseline gas exchange parameters and target baseline values for arterial oxygen and carbon dioxide parameters.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Physical therapy – Critically ill patients with neuromuscular disease are particularly at increased risk for developing superimposed critical illness myopathy or polyneuropathy. Measures to reduce this risk and prevent post intensive care unit syndrome should be undertaken. (See
         <a class="medical medical_review" href="/z/d/html/5144.html" rel="external">
          "Neuromuscular weakness related to critical illness"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/88330.html" rel="external">
          "Post-intensive care syndrome (PICS) in adults: Clinical features and diagnostic evaluation"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Fluid and electrolytes – Particular care should be taken to correct electrolyte abnormalities (eg, hypophosphatemia, hypokalemia) and avoid factors that may further compromise respiratory muscle function, including neuromuscular blocking agents, aminoglycosides, and glucocorticoids.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Nutrition – Overfeeding must be avoided as the associated increase in carbon dioxide production can worsen hypercapnia [
         <a href="#rid13">
          13
         </a>
         ]. Nutrition in patients requiring continuous chronic ventilatory support is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/1440.html" rel="external">
          "Malnutrition in advanced lung disease"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/1617.html" rel="external">
          "Nutrition support in intubated critically ill adult patients: Initial evaluation and prescription"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/5116.html" rel="external">
          "Noninvasive ventilatory support and mechanical insufflation-exsufflation for patients with respiratory muscle dysfunction", section on 'Nutrition'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H4177816404">
         <span class="h3">
          Discontinuing invasive mechanical ventilation
         </span>
         <span class="headingEndMark">
          —
         </span>
         Discontinuation of mechanical ventilation follows a three-step process of readiness testing followed by a period of ventilatory support reduction, typically a spontaneous breathing trial (SBT), and extubation (or decannulation for those with a tracheostomy). However, when determining whether invasive mechanical ventilation can be discontinued in a patient with respiratory muscle weakness, extra caution is warranted because weaning failure is common (27 to 48 percent). While the optimal approach is unknown, the principles of readiness testing and SBTs are similar to patients who do not have neuromuscular disorders. However, we typically require that the patient tolerate an SBT of more than two hours (rather than 30 minutes) before considering extubation.
        </p>
        <p>
         Our rationale for this approach is that patients referred to chronic weaning units are a group of patients who classically have diaphragmatic weakness and in whom half fail weaning trials of a duration longer than two hours; we make the assumption that this likely applies to patients with neuromuscular disease.
        </p>
        <p>
         Although not routine, we also have a low threshold to extubate to NIV. In a case control study, 10 patients with neuromuscular disease who were extubated directly to NIV and received assisted coughing aids after extubation, were less likely to require reintubation and tracheostomy compared with 10 historic controls [
         <a href="#rid14">
          14
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/1652.html" rel="external">
          "Weaning from mechanical ventilation: Readiness testing"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/1650.html" rel="external">
          "Initial weaning strategy in mechanically ventilated adults"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/1646.html" rel="external">
          "Management of the difficult-to-wean adult patient in the intensive care unit"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/1638.html" rel="external">
          "Management and prognosis of patients requiring prolonged mechanical ventilation", section on 'Weaning'
         </a>
         .)
        </p>
        <p>
         Rates of weaning failure are high, ranging from 27 to 48 percent, and are largely supported by several small observational studies [
         <a href="#rid15">
          15-18
         </a>
         ]. As examples:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In a retrospective study of 44 patients with Guillain-Barré syndrome, 24 were extubated and 20 underwent tracheostomy without attempted extubation [
         <a href="#rid15">
          15
         </a>
         ]; 42 percent of the extubations failed. This rate is significantly higher than the average rate of extubation failure in the ICU, which is approximately 10 to 15 percent.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In a similar study of patients with myasthenic crisis, 27 percent of extubations failed [
         <a href="#rid16">
          16
         </a>
         ]. Advanced age and pulmonary complications (pneumonia, atelectasis) were associated with extubation failure.
        </p>
        <p>
        </p>
        <p>
         Aggressive secretion clearance may decrease the duration of mechanical ventilation. In a retrospective cohort study of 18 patients with 24 episodes of acute respiratory failure due to myasthenia gravis, an aggressive approach to airway care (combining intermittent positive pressure breathing, bronchodilators, suctioning, sighs and chest physiotherapy) was associated with less atelectasis, less pneumonia, and a shorter duration of mechanical ventilation than seen in historical controls [
         <a href="#rid19">
          19
         </a>
         ].
        </p>
        <p>
         Predictors of successful extubation include a MIP more negative than -50 cm H
         <sub>
          2
         </sub>
         O (eg, -60 cm H
         <sub>
          2
         </sub>
         O) and improvement of the VC by 4 mL/kg or more from pre-intubation to pre-extubation [
         <a href="#rid15">
          15
         </a>
         ].
        </p>
        <p>
         Predictors of failure may include age &gt;50 years, VC of less than 25 mL/kg during days one to six of intubation, evidence of chronic hypercapnia, dysautonomia, and poor baseline lung function [
         <a href="#rid15">
          15,20,21
         </a>
         ]. Failure rates are higher if more than one predictor is present. For example, in one case-control study of 53 patients admitted for 73 episodes of myasthenic crisis, the likelihood of requiring intubation beyond two weeks was 88 percent if three risk factors were present [
         <a href="#rid20">
          20
         </a>
         ].
        </p>
        <p>
         In another study of 37 patients with Guillain-Barré syndrome, a pulmonary function score (PFS) was calculated immediately prior to intubation and on the twelfth day of mechanical ventilation [
         <a href="#rid21">
          21
         </a>
         ]:
        </p>
        <div class="formulaContainer">
         <div class="formula">
          <p class="bulletIndent2">
           PFS = Vital capacity (mL/kg) + maximal inspiratory pressure (cm H
           <sub>
            2
           </sub>
           O) + maximal expiratory pressure (cm H
           <sub>
            2
           </sub>
           O)
          </p>
         </div>
        </div>
        <p>
        </p>
        <p>
         The PFS ratio between the two values of &lt;1 was associated with the need for more than three weeks of mechanical ventilation with a sensitivity and specificity of 100 and 70 percent, respectively. Validation of this index has not been undertaken. (See
         <a class="medical medical_review" href="/z/d/html/4389.html" rel="external">
          "Tracheostomy: Rationale, indications, and contraindications", section on 'Optimal timing in mechanically ventilated patients'
         </a>
         .)
        </p>
        <p>
         For patients who fail weaning or fail extubation with no identifiable reversible cause, tracheostomy is commonly considered beginning at 7 to 10 days, provided this is consistent with the patient’s wishes [
         <a href="#rid22">
          22
         </a>
         ]. However, some patients with chronic neuromuscular disease may be successfully extubated to NIV without an intervening need for tracheostomy (eg, those who have been NIV-dependent prior to the acute event and in whom the reason for ventilation was fully reversible). (See
         <a class="medical medical_review" href="/z/d/html/5116.html" rel="external">
          "Noninvasive ventilatory support and mechanical insufflation-exsufflation for patients with respiratory muscle dysfunction", section on 'Extubation to CNVS and MIE'
         </a>
         and
         <a class="local">
          'Tracheostomy'
         </a>
         below and
         <a class="local">
          'Patient values and preferences'
         </a>
         below.)
        </p>
        <p>
         Following extubation, most patients should have a formal swallowing evaluation since swallowing dysfunction is typically more common in this population than in patients without respiratory muscle weakness. (See
         <a class="medical medical_review" href="/z/d/html/1634.html" rel="external">
          "Extubation management in the adult intensive care unit", section on 'Refeeding'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3546386013">
         <span class="h3">
          Outcomes
         </span>
         <span class="headingEndMark">
          —
         </span>
         Even with timely intubation, patients with respiratory muscle weakness from neuromuscular disease tend to have relatively poor outcomes [
         <a href="#rid20">
          20,23-26
         </a>
         ]. These data are derived from small observational studies. For example, in studies of intubated patients with Guillain-Barré syndrome, mortality was reported to be 12 to 20 percent and the median duration of mechanical ventilation was 18 to 29 days [
         <a href="#rid24">
          24,25,27
         </a>
         ]. Among intubated patients with myasthenia gravis, mortality was 4 to 8 percent and the median duration of mechanical ventilation was 14 days, one week longer than patients without neuromuscular disease [
         <a href="#rid20">
          20,23
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H1180323894">
         <span class="h1">
          CHRONIC VENTILATORY SUPPORT
         </span>
         <span class="headingEndMark">
          —
         </span>
         All patients with respiratory muscle weakness from a neuromuscular disorder (NMD) should be evaluated for the need for chronic ventilatory assistance, typically with noninvasive ventilation (NIV). Patients with progressive disease should also be monitored clinically with pulmonary function tests (eg, every three to six months) and gas exchange parameters (eg, every six months) to determine the optimal time for ventilatory support. Most of the clinical data used to make the decision regarding NIV are already obtained during the clinical evaluation of patients with neuromuscular weakness. (See
         <a class="medical medical_review" href="/z/d/html/5121.html" rel="external">
          "Respiratory muscle weakness due to neuromuscular disease: Clinical manifestations and evaluation"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H4202718530">
         <span class="h2">
          Noninvasive ventilation
         </span>
        </p>
        <p class="headingAnchor" id="H657111866">
         <span class="h3">
          Indications
         </span>
         <span class="headingEndMark">
          —
         </span>
         Chronic respiratory failure in the context of a NMD known to cause respiratory muscle weakness  (
         <a class="graphic graphic_table graphicRef69167" href="/z/d/graphic/69167.html" rel="external">
          table 1
         </a>
         ), clinical symptoms, objective physiologic testing, and evidence of hypoventilation or sleep disordered breathing are collectively used to determine if or when NIV is initiated  (
         <a class="graphic graphic_table graphicRef79358" href="/z/d/graphic/79358.html" rel="external">
          table 5
         </a>
         ) [
         <a href="#rid28">
          28,29
         </a>
         ].
        </p>
        <p>
         In patients with symptomatic chronic respiratory failure from respiratory muscle weakness who have evidence of nocturnal and/or daytime hypoventilation, we suggest evaluation for chronic ventilatory assistance with NIV.
        </p>
        <p>
         Evaluation for NIV is also appropriate inpatients with progressive neuromuscular disorders who have early physiologic evidence of respiratory muscle weakness, even in the absence of symptoms or frank hypoventilation and in those who have symptoms suggestive of sleep disordered breathing in association with their underlying NMD.
        </p>
        <p>
         Mask NIV administered at night with supplementary use of mouthpiece ventilation is typically employed as an initial strategy. Practical applications of NIV are discussed separately.  (See
         <a class="medical medical_review" href="/z/d/html/5114.html" rel="external">
          "Noninvasive ventilation in adults with chronic respiratory failure from neuromuscular and chest wall diseases: Patient selection and alternative modes of ventilatory support"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H544793726">
         <span class="h4">
          Symptomatic chronic respiratory failure
         </span>
         <span class="headingEndMark">
          —
         </span>
         Several neuromuscular disorders are associated with the development of symptomatic chronic respiratory failure from respiratory muscle weakness  (
         <a class="graphic graphic_table graphicRef69167" href="/z/d/graphic/69167.html" rel="external">
          table 1
         </a>
         ).
        </p>
        <p class="headingAnchor" id="H1479794896">
         <span class="h5">
          Symptoms
         </span>
         <span class="headingEndMark">
          —
         </span>
         Symptoms suggestive of respiratory muscle weakness are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/5121.html" rel="external">
          "Respiratory muscle weakness due to neuromuscular disease: Clinical manifestations and evaluation", section on 'Clinical manifestations'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2654010014">
         <span class="h5">
          Physiologic evidence of respiratory muscle weakness
         </span>
         <span class="headingEndMark">
          —
         </span>
         Optimal parameters for chronic ventilatory support with NIV are unknown. Data indicate that no single measure at any one point in time is best for assessing the need for NIV. In our practice, we make clinical decisions after serial measurement of the maximum inspiratory pressure (MIP), maximum expiratory pressure (MEP), forced vital capacity (FVC), vital capacity (VC), and sniff nasal pressure (SNIP). (See
         <a class="medical medical_review" href="/z/d/html/5121.html" rel="external">
          "Respiratory muscle weakness due to neuromuscular disease: Clinical manifestations and evaluation", section on 'Clinical manifestations'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/5129.html" rel="external">
          "Symptom-based management of amyotrophic lateral sclerosis", section on 'Noninvasive positive pressure ventilation'
         </a>
         .)
        </p>
        <p>
         NIV is typically indicated when any one or more of the following is present [
         <a href="#rid30">
          30-35
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         FVC &lt;50 percent predicted
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         VC &lt;15 to 20 mL/kg, &lt;60 percent of predicted, or &lt;1 liter
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         MIP &lt;-60 cm H
         <sub>
          2
         </sub>
         O (eg, -50 cm H
         <sub>
          2
         </sub>
         O; indicates a high risk for hypercapnia)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         MEP &lt;40 cm H
         <sub>
          2
         </sub>
         O (indicates inadequate cough strength and risk for secretion retention)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         SNIP &lt;40 cm H
         <sub>
          2
         </sub>
         O
        </p>
        <p>
        </p>
        <p>
         These thresholds may vary depending upon the underlying neuromuscular disorder or institution. As an example, the threshold for VC was derived from studies of patients with Guillain-Barré syndrome. It is uncertain whether the VC is similarly helpful in patients with acute respiratory muscle weakness due to other peripheral neuromuscular diseases, such as myasthenia gravis [
         <a href="#rid35">
          35
         </a>
         ]. The threshold value for MIP also varies depending upon the institution and country (eg, in Europe a cutoff &lt;40 cm H
         <sub>
          2
         </sub>
         O is used).
        </p>
        <p>
         A "20-30-40 rule" has been proposed [
         <a href="#rid23">
          23,30
         </a>
         ]. The rule advocates the initiation of ventilatory support when the VC is less than 20 mL/kg, the MIP is less negative than -30 cm H
         <sub>
          2
         </sub>
         O (eg, -20 cm H
         <sub>
          2
         </sub>
         O), or the MEP is less than 40 cm H
         <sub>
          2
         </sub>
         O. Prospective studies are needed to determine if this rule decreases the need for emergent intubation and improves overall outcome.
        </p>
        <p class="headingAnchor" id="H911817252">
         <span class="h5">
          Chronic hypoventilation
         </span>
         <span class="headingEndMark">
          —
         </span>
         In the chronic setting, the presence of nocturnal or daytime hypoventilation is an indication for NIV. We typically document evidence of nocturnal hypoventilation from capnography studies performed during sleep while daytime hypercapnia is usually detected on an awake arterial blood gas. (See
         <a class="medical medical_review" href="/z/d/html/5121.html" rel="external">
          "Respiratory muscle weakness due to neuromuscular disease: Clinical manifestations and evaluation", section on 'Inadequate ventilation'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3675893724">
         <span class="h4">
          Asymptomatic patients with progressive disease
         </span>
         <span class="headingEndMark">
          —
         </span>
         In patients with progressive neuromuscular disorders, starting chronic ventilatory support before frank symptoms or hypoventilation develops may have a survival benefit (eg, FVC &lt;80 percent predicted, although the cutoff of FVC &lt;50 percent predicted is more commonly used) [
         <a href="#rid36">
          36
         </a>
         ]. Further details on monitoring respiratory function in patients with progressive neuromuscular disease are provided separately. (See
         <a class="medical medical_review" href="/z/d/html/5129.html" rel="external">
          "Symptom-based management of amyotrophic lateral sclerosis", section on 'Respiratory function management'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/5114.html" rel="external">
          "Noninvasive ventilation in adults with chronic respiratory failure from neuromuscular and chest wall diseases: Patient selection and alternative modes of ventilatory support", section on 'Patient selection'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H698364494">
         <span class="h4">
          Sleep disturbance
         </span>
         <span class="headingEndMark">
          —
         </span>
         In patients with NMD, symptoms suggestive of sleep disordered breathing such as obstructive sleep apnea may prompt evaluation for nocturnal NIV in the sleep laboratory with polysomnography [
         <a href="#rid37">
          37
         </a>
         ]. However, polysomnography is not necessary in the absence of symptoms suggestive of an underlying sleep disorder. (See
         <a class="medical medical_review" href="/z/d/html/7711.html" rel="external">
          "Evaluation of sleep-disordered breathing in adult patients with neuromuscular and chest wall disorders"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/7706.html" rel="external">
          "Clinical presentation and diagnosis of obstructive sleep apnea in adults", section on 'Diagnostic evaluation'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1332402985">
         <span class="h3">
          Contraindications
         </span>
         <span class="headingEndMark">
          —
         </span>
         Contraindications to NIV include severe bulbar dysfunction, upper airway obstruction, retention of respiratory secretions, inability to achieve a satisfactory interface, poor cooperation, and/or inadequate cough  (
         <a class="graphic graphic_table graphicRef60442" href="/z/d/graphic/60442.html" rel="external">
          table 2
         </a>
         ). Patient selection for NIV in patients with chronic neuromuscular disorders are discussed in detail separately. (See
         <a class="medical medical_review" href="/z/d/html/5114.html" rel="external">
          "Noninvasive ventilation in adults with chronic respiratory failure from neuromuscular and chest wall diseases: Patient selection and alternative modes of ventilatory support", section on 'Patient selection'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H37860998">
         <span class="h3">
          Efficacy
         </span>
         <span class="headingEndMark">
          —
         </span>
         Limited data in patients with chronic respiratory failure due to neuromuscular disorders suggest that nocturnal NIV improves daytime gas exchange, sleep, quality of life, and in some patients, survival [
         <a href="#rid38">
          38-53
         </a>
         ]. Best studied is amyotrophic lateral sclerosis (ALS):
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In a randomized trial of 92 patients with ALS who had orthopnea (with MIP &lt;60 percent of predicted) and/or symptomatic daytime hypercapnia, NIV plus standard care was compared with standard care alone [
         <a href="#rid47">
          47
         </a>
         ]. NIV improved survival by 205 days in patients without bulbar involvement, while no survival benefit was noted in those with bulbar disease. Patients with bulbar dysfunction who received NIV had some quality of life improvement, but without a survival benefit.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In a series of 71 patients with ALS treated with NIV for chronic respiratory failure, independent predictors of improved survival were tolerance of nocturnal NIV (risk ratio 0.32, 95% CI, 0.13-0.78) and a slower rate of decline of FVC [
         <a href="#rid48">
          48
         </a>
         ]. Patients with mild or no bulbar symptoms were more likely to be tolerant of NIV.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Diaphragmatic pacing (in addition to NIV) does not augment survival in patients with ALS [
         <a href="#rid54">
          54,55
         </a>
         ]. These data are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/5117.html" rel="external">
          "Pacing the diaphragm: Patient selection, evaluation, implantation, and complications"
         </a>
         .)
        </p>
        <p>
        </p>
        <p>
         Limited data in patients with respiratory muscle weakness from thoracic cage disease suggest a similar benefit:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A prospective study of 244 patients with chronic respiratory failure due to kyphoscoliosis reported improved survival with home NIV compared with long-term oxygen therapy (hazard ratio 0.30, 95% CI 0.18-0.51) [
         <a href="#rid56">
          56
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Small observational studies of patients with restrictive thoracic cage disease show improved sleep efficiency, stage N3 and/or rapid eye movement (REM) sleep during NIV [
         <a href="#rid57">
          57-59
         </a>
         ].
        </p>
        <p>
        </p>
        <p>
         The exact mechanism by which nocturnal NIV can correct daytime hypoventilation in patients with neuromuscular and chest wall disease has not been fully elucidated. It is hypothesized that central chemoreceptor sensitivity may be restored by correction of profound nocturnal hypercapnia, or that the quality of sleep is changed when nocturnal NIV is employed [
         <a href="#rid60">
          60,61
         </a>
         ]. Observational studies also suggest that nocturnal mechanical ventilation at least partially improves lung mechanics, respiratory muscle strength, or reduces ventilation‐perfusion mismatch, by day as well as night [
         <a href="#rid41">
          41
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/5112.html" rel="external">
          "Control of ventilation"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1102145202">
         <span class="h3">
          Outcomes
         </span>
         <span class="headingEndMark">
          —
         </span>
         Patients with respiratory muscle weakness from neuromuscular disease can survive for years on NIV. Most require nocturnal support and some also require NIV for limited periods during the day. A small proportion of patients may benefit from continuous NIV (almost 24/7). (See
         <a class="medical medical_review" href="/z/d/html/5116.html" rel="external">
          "Noninvasive ventilatory support and mechanical insufflation-exsufflation for patients with respiratory muscle dysfunction"
         </a>
         .)
        </p>
        <p>
         Patients with nonprogressive myopathic or lower motor neuron lesions can be managed with NIV indefinitely. In contrast, patients with progressive upper motor neuron lesions, such as those with bulbar ALS or Duchenne muscular dystrophy (DMD), develop stridor and spastic upper airway collapse that can render NIV less effective and necessitate tracheostomy for continued survival. (See
         <a class="local">
          'Tracheostomy'
         </a>
         below.)
        </p>
        <p>
         Technical aspects of initiating NIV in patients with neuromuscular disease who have nocturnal hypoventilation or early chronic respiratory failure are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/5114.html" rel="external">
          "Noninvasive ventilation in adults with chronic respiratory failure from neuromuscular and chest wall diseases: Patient selection and alternative modes of ventilatory support"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/5118.html" rel="external">
          "Noninvasive ventilation in adults with chronic respiratory failure from neuromuscular and chest wall diseases: Practical aspects of initiation"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/5123.html" rel="external">
          "Noninvasive ventilation in adults with chronic respiratory failure from neuromuscular and chest wall diseases: Adaptation and follow-up after initiation"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3979932725">
         <span class="h2">
          Tracheostomy
         </span>
         <span class="headingEndMark">
          —
         </span>
         In patients with respiratory muscle weakness due to neuromuscular disease, tracheostomy should be considered in the chronic setting or following an acute event.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Indications – Indications include the following:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Patients who have difficulty clearing their secretions despite adjunctive therapies. (See
         <a class="local">
          'Respiratory adjunctive therapy'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Patients who require intermittent long-term mechanical ventilation, but in whom NIV is contraindicated (eg, severe bulbar dysfunction) or declined  (
         <a class="graphic graphic_table graphicRef60442" href="/z/d/graphic/60442.html" rel="external">
          table 2
         </a>
         ).
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Patients whose chronic respiratory failure has worsened and intermittent long-term NIV with respiratory adjunctive therapy is no longer sufficient.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Patients who fail to wean from mechanical ventilation following an acute event.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         In the chronic setting, the purpose of tracheostomy is chronic ventilation and/or secretion management as well ventilation for acute intercurrent illnesses. In the acute setting, the focus is also weaning to the point of decannulation and spontaneous breathing with or without NIV, although complete liberation from mechanical ventilation is not always achievable.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Making the decision – While the decision to proceed with tracheostomy is best made prior to any acute event that might prompt invasive mechanical ventilation with an endotracheal tube, this may not always be feasible for patients who present unexpectedly with acute disease (eg, spinal trauma, Guillain-Barré syndrome, myasthenic crisis). In addition, some patients change their mind over time or when faced with death in the near or immediate future. Thus, revisiting this decision is important during chronic care of these patients. (See
         <a class="medical medical_review" href="/z/d/html/5114.html" rel="external">
          "Noninvasive ventilation in adults with chronic respiratory failure from neuromuscular and chest wall diseases: Patient selection and alternative modes of ventilatory support", section on 'Patient preferences'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/5116.html" rel="external">
          "Noninvasive ventilatory support and mechanical insufflation-exsufflation for patients with respiratory muscle dysfunction", section on 'Indications for tracheostomy'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/86248.html" rel="external">
          "Advance care planning and advance directives"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Outcomes (liberation and life expectancy) – Data describing outcome in tracheostomized patients with respiratory muscle weakness are limited. While patients with acute reversible etiologies, such as Guillain-Barré syndrome have a high likelihood of being liberated from mechanical ventilation, others with progressive neuromuscular disorders may not be as successful in weaning and end up partially or completely ventilator-dependent. In our experience, patients can survive for many years with a tracheostomy, although life-expectancy is likely limited when compared with spontaneously breathing patients who do not have a neuromuscular disorder.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Predicting who will be successfully liberated and who will not is poorly studied and may be dependent upon factors including age, nature of the underlying illness, and presence of other comorbidities. In one retrospective study of 60 patients with ALS who underwent tracheostomy for failure to wean from mechanical ventilation, on discharge from the acute care facility, 70 percent were completely ventilator-dependent, 28 percent were partially ventilator-dependent and 1.6 percent were liberated from mechanical ventilation [
         <a href="#rid62">
          62
         </a>
         ]. Liberation rates thereafter were not described, but survival rates were 65 percent at one year and 45 percent at two years after tracheostomy. Survival was significantly shorter in patients older than 60 years at the time tracheostomy was performed. Details regarding transitioning from tracheostomy to NIV are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/5116.html" rel="external">
          "Noninvasive ventilatory support and mechanical insufflation-exsufflation for patients with respiratory muscle dysfunction"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/5116.html" rel="external">
          "Noninvasive ventilatory support and mechanical insufflation-exsufflation for patients with respiratory muscle dysfunction", section on 'Tracheostomy to noninvasive ventilatory support'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Nutrition – Swallowing dysfunction is common after intubation and when a tracheostomy is present, even among patients without pre-existing neuromuscular disease. Many patients who require a tracheostomy long term for ventilation, also require enteral feeding via a gastrostomy or jejunostomy tube, although some patients may be able to swallow safely with a tracheostomy in place within a stable chronic setting [
         <a href="#rid63">
          63
         </a>
         ]. For patients with neuromuscular disorders who are successfully decannulated, an evaluation of bulbar function and swallowing should be undertaken before allowing them to eat [
         <a href="#rid64">
          64
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/5116.html" rel="external">
          "Noninvasive ventilatory support and mechanical insufflation-exsufflation for patients with respiratory muscle dysfunction"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Disposition of service – Patients with respiratory muscle weakness who have a tracheostomy do not necessarily need a long term care facility indefinitely. Some patients can be chronically ventilated at home, provided appropriate support is available. (See
         <a class="medical medical_review" href="/z/d/html/5116.html" rel="external">
          "Noninvasive ventilatory support and mechanical insufflation-exsufflation for patients with respiratory muscle dysfunction"
         </a>
         .)
        </p>
        <p>
        </p>
        <p>
         Technical details regarding tracheostomy placement are provided separately. (See
         <a class="medical medical_review" href="/z/d/html/4389.html" rel="external">
          "Tracheostomy: Rationale, indications, and contraindications"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H9">
         <span class="h2">
          Respiratory adjunctive therapy
         </span>
         <span class="headingEndMark">
          —
         </span>
         In patients with respiratory muscle weakness who have ineffective cough, we suggest the routine use of adjuncts to assist coughing for secretion clearance. Benefits to support their routine use outside of this indication are unclear, although other physiologic benefits such as transiently improved respiratory compliance may exist. Such adjuncts can be used in the chronic setting as well as during and/or recovering from acute respiratory tract illnesses.
        </p>
        <p>
         Interventions include mechanical insufflation-exsufflation (MIE), manually assisted coughing, hyperinflation maneuvers for lung volume recruitment (LVR), and secretion clearance techniques. We generally prefer MIE, although it has not been directly compared to the other interventions and in many cases we use a combination of such therapies depending on the patient’s preference, muscle weakness group, (inspiratory and/or expiratory), cough and glottis strength, volume of secretions, and level of expertise [
         <a href="#rid38">
          38,65
         </a>
         ].
        </p>
        <p>
         When prescribed, most are applied daily or twice daily. In the chronic setting, acceptance or adherence to these maneuvers is likely an issue that affects efficacy [
         <a href="#rid66">
          66
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H1755550860">
         <span class="h3">
          Techniques to augment cough
         </span>
         <span class="headingEndMark">
          —
         </span>
         Maneuvers that improve inspiratory and/or expiratory flow can augment cough. However, the efficacy of such maneuvers, may be more limited in patients who cannot obtain effective glottic closure, which is required to generate high intrathoracic pressure during cough (eg, bulbar dysfunction in patients with ALS and DMD). The physiology of cough is described separately. (See
         <a class="medical medical_review" href="/z/d/html/5121.html" rel="external">
          "Respiratory muscle weakness due to neuromuscular disease: Clinical manifestations and evaluation", section on 'Muscles of respiration and cough'
         </a>
         and
         <a class="local">
          'Lung volume recruitment (assisted inflation maneuvers)'
         </a>
         below and
         <a class="local">
          'Manual-assisted cough (abdominal thrust)'
         </a>
         below and
         <a class="local">
          'Mechanical insufflation-exsufflation'
         </a>
         below.)
        </p>
        <p>
         Adequacy of cough can be determined by regularly measuring cough peak flow (PCF). Values &gt;160 L/min are necessary for an effective cough to clear respiratory secretions. It has been suggested that a “baseline” PCF &gt;270 L/min, when the patient is well, is required to maintain a PCF &gt;160 L/min when the patient is unwell [
         <a href="#rid67">
          67
         </a>
         ]. Assessing cough strength is mostly done as part of the diagnostic evaluation of respiratory muscle weakness but may also need to be monitored in those with progressive disease. (See
         <a class="medical medical_review" href="/z/d/html/5121.html" rel="external">
          "Respiratory muscle weakness due to neuromuscular disease: Clinical manifestations and evaluation", section on 'Assessing cough strength'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H10">
         <span class="h4">
          Mechanical insufflation-exsufflation
         </span>
         <span class="headingEndMark">
          —
         </span>
         Insufflation-exsufflation can be delivered via a mechanical device to patients who are spontaneously breathing (ie, MIE)  (
         <a class="graphic graphic_figure graphicRef129501" href="/z/d/graphic/129501.html" rel="external">
          figure 1
         </a>
         ). Both phases, insufflation and exsufflation, are active (ie, device assisted). During insufflation, positive pressure is applied (usually +40 cm H
         <sub>
          2
         </sub>
         O), which results in an inspired tidal volume. Exsufflation rapidly follows over 0.02 seconds. Pressure becomes negative (usually -40 cm H
         <sub>
          2
         </sub>
         O) and is sufficient to generate about 10 L per second of exsufflation (ie, expiratory) flow. Note, these expiratory flows are higher than that which would be achieved with passive expiration. The goal is to fully inflate then fully empty the lungs in four to six seconds to clear airway debris. Treatments are typically administered once or a twice a day but frequency can be increased in the setting of active respiratory infection or after extubation or decannulation.
        </p>
        <p>
         Using the same device, MIE can also be applied through an endotracheal or tracheostomy tube when patients are on a mechanical ventilator. However, higher insufflation pressures are generally used (eg, 60 to 70 cm H
         <sub>
          2
         </sub>
         O) to compensate for a drop in pressure across the endotracheal or tracheostomy tube.
        </p>
        <p>
         MIE can be used alone or in combination with manually assisted coughing (see
         <a class="local">
          'Manual-assisted cough (abdominal thrust)'
         </a>
         below). However, when MIE is administered at sufficiently high pressures (eg, 50 to 60 cm H
         <sub>
          2
         </sub>
         O), the concomitant abdominal thrusts from the manual assist maneuver usually do not further increase the exsufflation flow, and so, are probably not necessary.
        </p>
        <p>
         MIE is generally well tolerated with complications infrequently reported and can be used in the home [
         <a href="#rid68">
          68
         </a>
         ]. Gastric distension and chest wall discomfort can occasionally occur. There are rare reports of pneumothorax [
         <a href="#rid69">
          69
         </a>
         ].
        </p>
        <p>
         MIE may be less effective in patients who have expiratory airflow limitation (eg, chronic obstructive pulmonary disease) because it is associated with worsening expiratory airway collapse and a decrease in the PCF [
         <a href="#rid70">
          70,71
         </a>
         ]. In addition, with disease progression and/or bulbar dysfunction, laryngeal dysfunction can result from MIE when higher inflation pressures are used (eg, laryngeal adduction during insufflation and hypopharyngeal collapse during exsufflation) [
         <a href="#rid72">
          72
         </a>
         ]. With any of these circumstances, we lower MIE pressures, and if this is not effective, we use alternative cough augmentation maneuvers such as manually assisted coughing. (See
         <a class="local">
          'Manual-assisted cough (abdominal thrust)'
         </a>
         below.)
        </p>
        <p>
         Data to support the routine use of MIE, either during stable disease or during acute respiratory tract infections are limited to observation studies with minimal data describing its effect on clinically important outcomes such as disease progression, need for invasive mechanical ventilation, or survival [
         <a href="#rid73">
          73-79
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         MIE plus chest physical therapy reduces treatment failure in patients with neuromuscular disease who have a respiratory tract infection, compared with historical controls managed with chest physical therapy alone [
         <a href="#rid76">
          76
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         MIE via a tracheostomy tube is more effective at clearing respiratory secretions than tracheal suctioning in patients with ALS [
         <a href="#rid77">
          77
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         MIE produces a greater increase in PCF than a manually assisted cough in some, but not all, studies [
         <a href="#rid74">
          74,78
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         MIE improves physiologic parameters including vital capacity, peripheral oxygenation, exhaled tidal volume, and peak expiratory flow in patients with neuromuscular disease [
         <a href="#rid79">
          79-81
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Use of a protocol that included MIE (or other lung-assist devices) and manual assisted coughing lowered the hospitalization rate among patients with DMD [
         <a href="#rid73">
          73
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         MIE has been shown to eliminate the need for deep airway suctioning and can return ambient air oxyhemoglobin saturation to normal when preparing patients for successful extubation or decannulation [
         <a href="#rid82">
          82,83
         </a>
         ].
        </p>
        <p>
        </p>
        <p>
         The insufflation component of MIE can also be used for passive lung volume recruitment (LVR) which is discussed below. (See
         <a class="local">
          'Lung volume recruitment (assisted inflation maneuvers)'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H11">
         <span class="h4">
          Manual-assisted cough (abdominal thrust)
         </span>
         <span class="headingEndMark">
          —
         </span>
         The manual-assisted cough (also called "quad cough") is an abdominal thrust that is provided by a caregiver and timed to occur at the same time as the patient's voluntary cough effort. It has variable efficacy in different populations.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In patients who have expiratory muscle weakness, manual-assisted cough is effective as an isolated maneuver, and can be augmented when combined with insufflation techniques [
         <a href="#rid84">
          84
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In patients who have inspiratory muscle weakness (eg, when the vital capacity is 1.5 L or less), manual-assisted cough is insufficient as an isolated maneuver and should be combined with insufflation or recruitment maneuvers.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Similarly, manual-assisted coughing may also not be sufficiently effective in the presence of severe scoliosis or severely impaired bulbar-innervated muscles.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In addition, it should be avoided following meals due to the risk of aspiration and cannot be used in patients with abdominal trauma.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H12">
         <span class="h4">
          Lung volume recruitment (assisted inflation maneuvers)
         </span>
         <span class="headingEndMark">
          —
         </span>
         Assisted lung inflation maneuvers are LVR maneuvers that increase inspiratory tidal volume. LVR is designed to improve lung compliance, reduce restriction, decrease the work of breathing, and improve cough flow.
        </p>
        <p>
         LVR maneuvers can be device-assisted (active) or spontaneously performed (passive), none of which has been proven superior. With the exception of glossopharyngeal breathing, a manual resuscitator (eg, Ambu bag) or volume-cycled ventilator is typically used to deliver preset volumes for inflation; pressure-cycled ventilators cannot be used for LVR [
         <a href="#rid85">
          85,86
         </a>
         ]. Delivered volumes are typically higher than a normal tidal volume and generally approach maximum lung insufflation capacity (ie, until the glottis can hold no additional air). This provides a greater volume of gas to be forced out during a cough, thereby also improving cough effectiveness. In LVR, exhalation is passive unless combined with manual-assisted coughing or exsufflation. Spontaneous LVR maneuvers such as glossopharyngeal breathing, require intact bulbar function for the patient to be able to retain the delivered tidal volume [
         <a href="#rid87">
          87
         </a>
         ]. However, this is not an issue for LVR maneuvers delivered by a device through an endotracheal tube or tracheotomy tube.
        </p>
        <p>
         There are several ways to deliver LVR maneuvers, which include the following:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Mechanical inspiration using a mechanical insufflator or a volume cycled ventilator
         </strong>
         – These device-assisted LVR maneuvers are especially useful for patients unable to stack breaths such as patients with poor bulbar dysfunction when glottis strength is inadequate to hold consecutively delivered air volumes [
         <a href="#rid75">
          75
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         The insufflation component of MIE may be used for LVR. Alternatively, a volume-cycled ventilator (invasive or noninvasive) may be used to deliver a preset inspiratory tidal volume. Exhalation can be passive or assisted (eg, manual-assisted cough, exsufflation). Intermittent positive pressure breathing (IPPB) devices have also been used to deliver a set pressure to expand the lungs (and can also be used to deliver aerosolized medications); however, IPPB devices have largely been supplanted by NIV.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Stacked breaths
         </strong>
         – Stacked breathing is initiation of inspiration before the completion of expiration. Glossopharyngeal (GPB) or "frog breathing" is a breath-stacking technique learned spontaneously by or taught to patients with respiratory muscle weakness [
         <a href="#rid88">
          88
         </a>
         ]. To perform effective GPB, the upper airway and tongue musculature must be intact. Thus, the main users of GPB are a rapidly diminishing population of patients with post-polio syndrome, those with high cervical cord lesions, and others with neuromuscular diseases that spare the upper airway musculature. Some patients use GPB to become independent from mechanical ventilation for up to several hours at a time while awake. Others with progressive neuromuscular disease use it for prolonged periods to delay the eventual need for mechanical ventilation [
         <a href="#rid89">
          89
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         During GPB, the patient performs gulping maneuvers that inject 50 to 60 mL boluses of air into the lungs. Each "gulp" takes 0.5 seconds and is repeated 10 to 12 times to achieve a normal tidal volume or maximal tolerated inspiratory capacity. The intake of tidal volume is repeated 10 times per minute for a total volume of 5 to 6 L/min.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Delivery of stacked breaths can be also achieved using a manual resuscitation bag (eg, Ambu bag). Compression of the manual resuscitation bag transmits inspiratory pressure to the airways through an airtight oronasal mask or mouthpiece. Exhalation is prevented by either the one-way valve or the patient controlling their glottis. Once the maximum tolerated assisted inspiratory capacity is reached, passive exhalation to functional residual capacity or a spontaneous or assisted forced expiratory maneuver (eg, cough) follows. Breath-stacking can also be performed using a volume-cycled NIV device.
        </p>
        <p>
        </p>
        <p>
         Data to support the use of LVR are limited to observational series that mostly describe efficacy on surrogate outcomes such as inspiratory capacity and PCF with limited data to support an effect on concrete clinical outcomes (eg, pneumonia rate, hospitalizations, mortality). In reality, the efficacy likely varies, being effective for some and less effective for others [
         <a href="#rid90">
          90
         </a>
         ]. However, identifying who benefits and who does not is unclear.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In patients with DMD, two observational cohorts suggested slower rates of decline in forced vital capacity (FVC) following the initiation of daily LVR (-4.5 versus -0.5 percent predicted per year) [
         <a href="#rid86">
          86,91
         </a>
         ]. The PCF was unaffected by LVR. Similar results were seen in patients with multiple sclerosis treated with twice daily LVR [
         <a href="#rid92">
          92
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In a small randomized controlled trial of patients with ALS, no difference was found in the number of episodes of chest infection, duration of symptoms during each episode of infection, need for hospitalization, quality of life, or median survival when breath-stacking using a lung volume recruitment bag was compared to the mechanical insufflator-exsufflator [
         <a href="#rid66">
          66
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In 52 adult patients with DMD receiving NIV, no difference in cough effectiveness was seen when breath stacking from a home ventilator was compared with that generated from a lung volume recruitment bag [
         <a href="#rid93">
          93
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In 18 patients with severe respiratory muscle dysfunction from neuromuscular disease, PCFs were highest using a combination of LVR using a volume-cycled ventilator and manually assisted cough compared with either MIE or MIE combined with manually assisted cough [
         <a href="#rid94">
          94
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1176080003">
         <span class="h3">
          Managing secretions
         </span>
         <span class="headingEndMark">
          —
         </span>
         Managing oral and pulmonary secretions can be an issue in patients with respiratory muscle weakness, especially in patients with bulbar dysfunction and those with acute respiratory infections. We typically use one or more techniques to mobilize secretions and reduce secretion volume, which are discussed in the sections below.
        </p>
        <p class="headingAnchor" id="H13">
         <span class="h4">
          Secretion mobilization techniques
         </span>
         <span class="headingEndMark">
          —
         </span>
         High frequency chest-wall oscillation (HFCWO), intrapulmonary percussive ventilation, and MIE are techniques that can mobilize secretions from the airways [
         <a href="#rid87">
          87
         </a>
         ].
         <em>
         </em>
         Data describing efficacy are limited. A 12 week, controlled trial of HFCWO in 46 patients with ALS showed reduced dyspnea, but no slowing of deterioration in pulmonary function
         <em>
         </em>
         [
         <a href="#rid95">
          95
         </a>
         ]. Data also suggest that MIE may be effective for secretion clearance during respiratory tract infections
         <em>
         </em>
         [
         <a href="#rid96">
          96
         </a>
         ] and may reduce the rate of intubation or bronchoscopy when compared to those treated without MIE
         <em>
         </em>
         [
         <a href="#rid76">
          76
         </a>
         ]
         <em>
          .
         </em>
        </p>
        <p>
         HFCWO is an external chest wall device that delivers oscillations to the chest using an inflatable vest that wraps around the chest. The device produces vibrations at variable frequencies and intensities, to facilitate expectoration. An intrapulmonary percussive ventilation device is a pneumatic device that can be connected to a face mask, mouthpiece, endotracheal tube or tracheostomy that intermittently delivers small tidal volumes at high frequencies (100 to 300 cycles per minute) creating percussions inside the lung. MIE is described above. (See
         <a class="local">
          'Mechanical insufflation-exsufflation'
         </a>
         above.)
        </p>
        <p class="headingAnchor" id="H1064365914">
         <span class="h4">
          Reducing secretion volume
         </span>
         <span class="headingEndMark">
          —
         </span>
         Oral secretions can be reduced using anticholinergic agents (transdermal
         <a class="drug drug_general" data-topicid="9915" href="/z/d/drug information/9915.html" rel="external">
          scopolamine
         </a>
         , nebulized or subcutaneous
         <a class="drug drug_general" data-topicid="8496" href="/z/d/drug information/8496.html" rel="external">
          glycopyrrolate
         </a>
         , topical
         <a class="drug drug_general" data-topicid="8983" href="/z/d/drug information/8983.html" rel="external">
          atropine
         </a>
         , oral
         <a class="drug drug_general" data-topicid="8605" href="/z/d/drug information/8605.html" rel="external">
          amitriptyline
         </a>
         , oral
         <a class="drug drug_general" data-topicid="8545" href="/z/d/drug information/8545.html" rel="external">
          hyoscyamine
         </a>
         sulfate), injection of botulinum toxin into the submandibular or parotid glands, or external beam radiation to the salivary glands. Approximately two-thirds of patients respond to these interventions [
         <a href="#rid97">
          97
         </a>
         ]. However, anticholinergics must be used carefully because of associated side effects (eg, constipation, dry mouth). Salivary gland botulinum toxin injection can provide benefit for three to four months, but laryngeal dysfunction can occur as an adverse effect [
         <a href="#rid98">
          98,99
         </a>
         ]. The medication should be discontinued if the patient does not experience symptomatic improvement.
        </p>
        <p class="headingAnchor" id="H887378164">
         <span class="h1">
          PATIENT VALUES AND PREFERENCES
         </span>
         <span class="headingEndMark">
          —
         </span>
         For patients with respiratory failure due to neuromuscular disease, clinicians should understand the patients’ values and goals for medical care both in the acute and chronic care setting (eg, restoring health, extending life, or relieving pain and suffering). Palliative care teams can help to facilitate discussions regarding patients’ goals and preferences and can provide ongoing care if the goals are to focus on palliation. (See
         <a class="medical medical_review" href="/z/d/html/2202.html" rel="external">
          "Ethical issues in palliative care"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/14240.html" rel="external">
          "Benefits, services, and models of subspecialty palliative care"
         </a>
         .)
        </p>
        <p>
         Some patients with neuromuscular disease can expect continued progression of their underlying disease process even with long term respiratory support (eg, amyotrophic lateral sclerosis, Duchenne muscular dystrophy [DMD]), although the rate of disease progression varies. In this population, some patients may not choose permanent assisted ventilation with tracheostomy, based on issues related to quality of life and expectations of worsening disability, while others find it acceptable.
        </p>
        <p>
         Progressive neuromuscular diseases of childhood, such as spinal muscular atrophy and milder variants of DMD present different challenges. In these diseases, long-term ventilatory support is more common and often associated with good quality of life, and decisions are often made during childhood by parents. For these patients, as with adult patients, a clear understanding of the decision-maker’s expectations is essential.
        </p>
        <p class="headingAnchor" id="H106619354">
         <span class="h1">
          SOCIETY GUIDELINE LINKS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See
         <a class="medical medical_society_guidelines" href="/z/d/html/119337.html" rel="external">
          "Society guideline links: Noninvasive ventilation in adults"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H16">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Respiratory muscle weakness can be commonly encountered among patients who have neuromuscular disease due to a variety of etiologies  (
         <a class="graphic graphic_table graphicRef69167" href="/z/d/graphic/69167.html" rel="external">
          table 1
         </a>
         ). Supportive management of respiratory muscle weakness due to neuromuscular disease can provide symptomatic relief, improve quality of life, and in some cases, prolong life. In all cases, treatment of the underlying neuromuscular disorder is indicated, if feasible, although the response may vary depending on the specific disease entity. (See
         <a class="local">
          'Introduction'
         </a>
         above and
         <a class="local">
          'Treatment of the underlying disorder'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Acute respiratory failure
         </strong>
         – Patients with respiratory muscle weakness may present with acute respiratory failure due to the underlying neuromuscular disease itself, a complication of their disease, or another intercurrent illness. Initial evaluation involves deciding whether the patient is suitable for noninvasive (NIV) or invasive ventilation. Indications for either form of ventilation in the acute setting are similar to those in the general population. However, the features of respiratory distress may be subtle such that the threshold for obtaining an arterial blood gas should be low. (See
         <a class="medical medical_review" href="/z/d/html/292.html" rel="external">
          "Approach to the adult with dyspnea in the emergency department"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/1458.html" rel="external">
          "The evaluation, diagnosis, and treatment of the adult patient with acute hypercapnic respiratory failure"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/1636.html" rel="external">
          "Noninvasive ventilation in adults with acute respiratory failure: Benefits and contraindications"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/268.html" rel="external">
          "The decision to intubate"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         The indications, contraindications  (
         <a class="graphic graphic_table graphicRef60442" href="/z/d/graphic/60442.html" rel="external">
          table 2
         </a>
         ), and technical aspects of initiating NIV  (
         <a class="graphic graphic_table graphicRef51201" href="/z/d/graphic/51201.html" rel="external">
          table 3
         </a>
         ) are similar to those in patients without respiratory muscle weakness. Notably, patients with significant bulbar dysfunction are poor candidates for NIV since they are unable to protect their lower airway and are at high risk of aspiration with NIV and upper airway collapse. (See
         <a class="local">
          'Noninvasive ventilation'
         </a>
         above and
         <a class="medical medical_review" href="/z/d/html/1636.html" rel="external">
          "Noninvasive ventilation in adults with acute respiratory failure: Benefits and contraindications"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/126295.html" rel="external">
          "Noninvasive ventilation in adults with acute respiratory failure: Practical aspects of initiation"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Similarly, indications for immediate intubation and invasive mechanical ventilation, ventilation strategies, and supportive care are similar to those who have acute respiratory failure without respiratory muscle weakness. However, select issues should be taken into consideration (see
         <a class="local">
          'Invasive mechanical ventilation'
         </a>
         above):
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Suitable induction agents  (
         <a class="graphic graphic_table graphicRef65645" href="/z/d/graphic/65645.html" rel="external">
          table 4
         </a>
         ) that may avoid prolonged hypotension in susceptible patients include
         <a class="drug drug_general" data-topicid="8588" href="/z/d/drug information/8588.html" rel="external">
          ketamine
         </a>
         ,
         <a class="drug drug_general" data-topicid="8428" href="/z/d/drug information/8428.html" rel="external">
          etomidate
         </a>
         , combined ketamine with
         <a class="drug drug_general" data-topicid="9826" href="/z/d/drug information/9826.html" rel="external">
          propofol
         </a>
         , or reduced-dose propofol (eg, hypovolemic and debilitated). While neuromuscular blocking agents are not contraindicated, the response can be variable.
         <a class="drug drug_general" data-topicid="9952" href="/z/d/drug information/9952.html" rel="external">
          Succinylcholine
         </a>
         is generally avoided due to the increased risk of malignant hyperthermia, hyperkalemia, and rhabdomyolysis in some patients with select neuromuscular disorders. (See
         <a class="local">
          'Indications'
         </a>
         above and
         <a class="medical medical_review" href="/z/d/html/271.html" rel="external">
          "Induction agents for rapid sequence intubation in adults for emergency medicine and critical care"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         We avoid electrolyte abnormalities (eg, hypophosphatemia, hypokalemia) and other factors that may further compromise respiratory muscle function, including neuromuscular blocking agents, aminoglycosides, and glucocorticoids. (See
         <a class="local">
          'General ICU supportive measures'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Extra caution is warranted when deciding whether to discontinue mechanical ventilation because the likelihood of weaning failure is high among patients with respiratory muscle weakness (27 to 48 percent). (See
         <a class="local">
          'Discontinuing invasive mechanical ventilation'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Chronic respiratory failure
         </strong>
         – All patients with chronic respiratory insufficiency due to respiratory muscle weakness from neuromuscular disease should be evaluated for the need for ventilatory support, typically with NIV. Patients with progressive disease should be monitored clinically with pulmonary function tests (eg, every three to six months) and gas exchange parameters (eg, every six months) to determine the optimal time for initiating chronic ventilatory support. (See
         <a class="local">
          'Chronic ventilatory support'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         In the context of an appropriate diagnosis  (
         <a class="graphic graphic_table graphicRef69167" href="/z/d/graphic/69167.html" rel="external">
          table 1
         </a>
         ), subjective clinical findings, objective physiologic tests, and evidence of hypoventilation or sleep disordered breathing are used to determine when NIV is indicated  (
         <a class="graphic graphic_table graphicRef79358" href="/z/d/graphic/79358.html" rel="external">
          table 5
         </a>
         ). (See
         <a class="local">
          'Noninvasive ventilation'
         </a>
         above and
         <a class="local">
          'Indications'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Symptomatic respiratory failure with evidence of hypoventilation
         </strong>
         – For patients with symptomatic chronic respiratory failure due to neuromuscular weakness with evidence of nocturnal and/or daytime hypoventilation, we suggest evaluation for chronic ventilatory assistance with NIV (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). (See
         <a class="local">
          'Symptomatic chronic respiratory failure'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Progressive neuromuscular disorder
         </strong>
         – Evaluation for NIV is also appropriate in patients with progressive neuromuscular disorders who have early physiologic evidence of respiratory muscle weakness even in the absence of frank hypoventilation or symptoms. These parameters include (see
         <a class="medical medical_review" href="/z/d/html/5129.html" rel="external">
          "Symptom-based management of amyotrophic lateral sclerosis", section on 'Noninvasive positive pressure ventilation'
         </a>
         and
         <a class="local">
          'Physiologic evidence of respiratory muscle weakness'
         </a>
         above):
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Forced vital capacity &lt;50 percent predicted
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Vital capacity (VC) &lt;15 to 20 mL/kg, 60 percent of predicted, or &lt;1 L
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Maximal inspiratory pressure &lt;-60 cm H
         <sub>
          2
         </sub>
         O (eg, -50 cm H
         <sub>
          2
         </sub>
         O)
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Maximal expiratory pressure &lt;40 cm H
         <sub>
          2
         </sub>
         O
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Sniff nasal inspiratory pressure &lt;40 cm H
         <sub>
          2
         </sub>
         O
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Sleep disordered breathing
         </strong>
         – We also evaluate for NIV during polysomnography when co-existing sleep disordered breathing is suspected in patients with neuromuscular disorder. (See
         <a class="medical medical_review" href="/z/d/html/7711.html" rel="external">
          "Evaluation of sleep-disordered breathing in adult patients with neuromuscular and chest wall disorders"
         </a>
         and
         <a class="local">
          'Sleep disturbance'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Contraindications
         </strong>
         – Contraindications to NIV include severe bulbar dysfunction, upper airway obstruction, retention of respiratory secretions, inability to achieve a satisfactory interface, poor cooperation, and/or inadequate cough  (
         <a class="graphic graphic_table graphicRef60442" href="/z/d/graphic/60442.html" rel="external">
          table 2
         </a>
         ). (See
         <a class="local">
          'Contraindications'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Tracheostomy
         </strong>
         – Tracheostomy is indicated for patients with neuromuscular disease who have difficulty clearing their secretions, require intermittent long-term mechanical ventilation but in whom NIV is contraindicated, patients who have worsening chronic respiratory failure and in whom intermittent long-term NIV is no longer sufficient, or patients who fail to wean from invasive mechanical ventilation. (See
         <a class="local">
          'Tracheostomy'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In patients with respiratory muscle weakness who have ineffective cough, we suggest the routine use of adjuncts to assist coughing for secretion clearance (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). Benefits to support their routine use outside of this indication are unclear. Such adjuncts can be used in the chronic setting as well as during acute respiratory tract illnesses. They can also be used in spontaneously breathing or ventilated patients. (See
         <a class="local">
          'Respiratory adjunctive therapy'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Interventions include mechanical insufflation-exsufflation (MIE), manual-assisted coughing, hyperinflation maneuvers, and secretion clearance techniques. We typically prefer MIE, although it has not been directly compared with other interventions and in many cases we use a combination of therapies (eg, mechanical insufflation and manual-assisted cough). (See
         <a class="local">
          'Techniques to augment cough'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         We typically use one or more techniques to mobilize secretions and reduce secretion volume. (See
         <a class="local">
          'Reducing secretion volume'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         For patients with respiratory failure due to respiratory muscle weakness from neuromuscular disease, it is particularly important for clinicians to understand the patients' values and goals for medical care (eg, restoring health, extending life, or relieving pain and suffering). We believe that discussions about patients’ desires regarding long-term care decisions are an integral part of the care of such patients. Palliative care teams can help to facilitate discussions regarding patients' goals and preferences and can provide ongoing care if the goals are to focus on palliation. (See
         <a class="local">
          'Patient values and preferences'
         </a>
         above.)
        </p>
        <p>
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Khan A, Frazer-Green L, Amin R, et al. Respiratory Management of Patients With Neuromuscular Weakness: An American College of Chest Physicians Clinical Practice Guideline and Expert Panel Report. Chest 2023; 164:394.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Perrin C, Unterborn JN, Ambrosio CD, Hill NS. Pulmonary complications of chronic neuromuscular diseases and their management. Muscle Nerve 2004; 29:5.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Epstein SK. An overview of respiratory muscle function. Clin Chest Med 1994; 15:619.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kannan Kanikannan MA, Durga P, Venigalla NK, et al. Simple bedside predictors of mechanical ventilation in patients with Guillain-Barre syndrome. J Crit Care 2014; 29:219.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kalita J, Kumar M, Misra UK. Serial single breath count is a reliable tool for monitoring respiratory functions in Guillain-Barré Syndrome. J Clin Neurosci 2020; 72:50.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Elsheikh B, Arnold WD, Gharibshahi S, et al. Correlation of single-breath count test and neck flexor muscle strength with spirometry in myasthenia gravis. Muscle Nerve 2016; 53:134.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Vrijsen B, Buyse B, Belge C, Testelmans D. Upper airway obstruction during noninvasive ventilation induced by the use of an oronasal mask. J Clin Sleep Med 2014; 10:1033.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Vianello A, Bevilacqua M, Arcaro G, et al. Non-invasive ventilatory approach to treatment of acute respiratory failure in neuromuscular disorders. A comparison with endotracheal intubation. Intensive Care Med 2000; 26:384.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Servera E, Sancho J, Zafra MJ, et al. Alternatives to endotracheal intubation for patients with neuromuscular diseases. Am J Phys Med Rehabil 2005; 84:851.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rabinstein A, Wijdicks EF. BiPAP in acute respiratory failure due to myasthenic crisis may prevent intubation. Neurology 2002; 59:1647.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sancho J, Servera E, Bañuls P, Marin J. Predictors of need for noninvasive ventilation during respiratory tract infections in medically stable, non-ventilated subjects with amyotrophic lateral sclerosis. Respir Care 2015; 60:492.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Orlikowski D, Sharshar T, Porcher R, et al. Prognosis and risk factors of early onset pneumonia in ventilated patients with Guillain-Barré syndrome. Intensive Care Med 2006; 32:1962.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Heyland DK, Dhaliwal R, Drover JW, et al. Canadian clinical practice guidelines for nutrition support in mechanically ventilated, critically ill adult patients. JPEN J Parenter Enteral Nutr 2003; 27:355.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Vianello A, Arcaro G, Braccioni F, et al. Prevention of extubation failure in high-risk patients with neuromuscular disease. J Crit Care 2011; 26:517.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nguyen TN, Badjatia N, Malhotra A, et al. Factors predicting extubation success in patients with Guillain-Barré syndrome. Neurocrit Care 2006; 5:230.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rabinstein AA, Mueller-Kronast N. Risk of extubation failure in patients with myasthenic crisis. Neurocrit Care 2005; 3:213.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gonçalves MR, Honrado T, Winck JC, Paiva JA. Effects of mechanical insufflation-exsufflation in preventing respiratory failure after extubation: a randomized controlled trial. Crit Care 2012; 16:R48.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Seneviratne J, Mandrekar J, Wijdicks EF, Rabinstein AA. Predictors of extubation failure in myasthenic crisis. Arch Neurol 2008; 65:929.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Varelas PN, Chua HC, Natterman J, et al. Ventilatory care in myasthenia gravis crisis: assessing the baseline adverse event rate. Crit Care Med 2002; 30:2663.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Thomas CE, Mayer SA, Gungor Y, et al. Myasthenic crisis: clinical features, mortality, complications, and risk factors for prolonged intubation. Neurology 1997; 48:1253.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lawn ND, Wijdicks EF. Post-intubation pulmonary function test in Guillain-Barré syndrome. Muscle Nerve 2000; 23:613.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           MacIntyre NR, Cook DJ, Ely EW Jr, et al. Evidence-based guidelines for weaning and discontinuing ventilatory support: a collective task force facilitated by the American College of Chest Physicians; the American Association for Respiratory Care; and the American College of Critical Care Medicine. Chest 2001; 120:375S.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mehta S. Neuromuscular disease causing acute respiratory failure. Respir Care 2006; 51:1016.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fletcher DD, Lawn ND, Wolter TD, Wijdicks EF. Long-term outcome in patients with Guillain-Barré syndrome requiring mechanical ventilation. Neurology 2000; 54:2311.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cheng BC, Chang WN, Chang CS, et al. Predictive factors and long-term outcome of respiratory failure after Guillain-Barré syndrome. Am J Med Sci 2004; 327:336.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Demoule A, Jung B, Prodanovic H, et al. Diaphragm dysfunction on admission to the intensive care unit. Prevalence, risk factors, and prognostic impact-a prospective study. Am J Respir Crit Care Med 2013; 188:213.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Orlikowski D, Prigent H, Sharshar T, et al. Respiratory dysfunction in Guillain-Barré Syndrome. Neurocrit Care 2004; 1:415.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Meyer TJ, Hill NS. Noninvasive positive pressure ventilation to treat respiratory failure. Ann Intern Med 1994; 120:760.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bach JR, Brougher P, Hess DR, et al. Consensus statement: Noninvasive positive pressure ventilation. Respir Care 1997; 42:364.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lawn ND, Fletcher DD, Henderson RD, et al. Anticipating mechanical ventilation in Guillain-Barré syndrome. Arch Neurol 2001; 58:893.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Miller RG, Rosenberg JA, Gelinas DF, et al. Practice parameter: the care of the patient with amyotrophic lateral sclerosis (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology: ALS Practice Parameters Task Force. Neurology 1999; 52:1311.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sharshar T, Chevret S, Bourdain F, et al. Early predictors of mechanical ventilation in Guillain-Barré syndrome. Crit Care Med 2003; 31:278.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chevrolet JC, Deléamont P. Repeated vital capacity measurements as predictive parameters for mechanical ventilation need and weaning success in the Guillain-Barré syndrome. Am Rev Respir Dis 1991; 144:814.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ropper AH. The Guillain-Barré syndrome. N Engl J Med 1992; 326:1130.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rieder P, Louis M, Jolliet P, Chevrolet JC. The repeated measurement of vital capacity is a poor predictor of the need for mechanical ventilation in myasthenia gravis. Intensive Care Med 1995; 21:663.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Vitacca M, Montini A, Lunetta C, et al. Impact of an early respiratory care programme with non-invasive ventilation adaptation in patients with amyotrophic lateral sclerosis. Eur J Neurol 2018; 25:556.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Berry RB, Chediak A, Brown LK, et al. Best clinical practices for the sleep center adjustment of noninvasive positive pressure ventilation (NPPV) in stable chronic alveolar hypoventilation syndromes. J Clin Sleep Med 2010; 6:491.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ambrosino N, Carpenè N, Gherardi M. Chronic respiratory care for neuromuscular diseases in adults. Eur Respir J 2009; 34:444.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ward S, Chatwin M, Heather S, Simonds AK. Randomised controlled trial of non-invasive ventilation (NIV) for nocturnal hypoventilation in neuromuscular and chest wall disease patients with daytime normocapnia. Thorax 2005; 60:1019.
          </a>
         </li>
         <li class="breakAll">
          Annane D, Chevrolet JC, Chevret S, Raphael JC. Nocturnal mechanical ventilation for chronic hypoventilation in patients with neuromuscular and chest wall disorders. Cochrane Database Syst Rev 2000:CD001941.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Annane D, Orlikowski D, Chevret S. Nocturnal mechanical ventilation for chronic hypoventilation in patients with neuromuscular and chest wall disorders. Cochrane Database Syst Rev 2014; :CD001941.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Aboussouan LS, Khan SU, Banerjee M, et al. Objective measures of the efficacy of noninvasive positive-pressure ventilation in amyotrophic lateral sclerosis. Muscle Nerve 2001; 24:403.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Aboussouan LS, Khan SU, Meeker DP, et al. Effect of noninvasive positive-pressure ventilation on survival in amyotrophic lateral sclerosis. Ann Intern Med 1997; 127:450.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Farrero E, Prats E, Povedano M, et al. Survival in amyotrophic lateral sclerosis with home mechanical ventilation: the impact of systematic respiratory assessment and bulbar involvement. Chest 2005; 127:2132.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kleopa KA, Sherman M, Neal B, et al. Bipap improves survival and rate of pulmonary function decline in patients with ALS. J Neurol Sci 1999; 164:82.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pinto AC, Evangelista T, Carvalho M, et al. Respiratory assistance with a non-invasive ventilator (Bipap) in MND/ALS patients: survival rates in a controlled trial. J Neurol Sci 1995; 129 Suppl:19.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bourke SC, Tomlinson M, Williams TL, et al. Effects of non-invasive ventilation on survival and quality of life in patients with amyotrophic lateral sclerosis: a randomised controlled trial. Lancet Neurol 2006; 5:140.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lo Coco D, Marchese S, Pesco MC, et al. Noninvasive positive-pressure ventilation in ALS: predictors of tolerance and survival. Neurology 2006; 67:761.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bach JR. Amyotrophic lateral sclerosis: prolongation of life by noninvasive respiratory AIDS. Chest 2002; 122:92.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Windisch W, Quality of life in home mechanical ventilation study group. Impact of home mechanical ventilation on health-related quality of life. Eur Respir J 2008; 32:1328.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tsolaki V, Pastaka C, Kostikas K, et al. Noninvasive ventilation in chronic respiratory failure: effects on quality of life. Respiration 2011; 81:402.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hannan LM, Dominelli GS, Chen YW, et al. Systematic review of non-invasive positive pressure ventilation for chronic respiratory failure. Respir Med 2014; 108:229.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Barbé F, Quera-Salva MA, de Lattre J, et al. Long-term effects of nasal intermittent positive-pressure ventilation on pulmonary function and sleep architecture in patients with neuromuscular diseases. Chest 1996; 110:1179.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           DiPALS Writing Committee, DiPALS Study Group Collaborators, McDermott CJ, et al. Safety and efficacy of diaphragm pacing in patients with respiratory insufficiency due to amyotrophic lateral sclerosis (DiPALS): a multicentre, open-label, randomised controlled trial. Lancet Neurol 2015; 14:883.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gonzalez-Bermejo J, Morélot-Panzini C, Tanguy ML, et al. Early diaphragm pacing in patients with amyotrophic lateral sclerosis (RespiStimALS): a randomised controlled triple-blind trial. Lancet Neurol 2016; 15:1217.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gustafson T, Franklin KA, Midgren B, et al. Survival of patients with kyphoscoliosis receiving mechanical ventilation or oxygen at home. Chest 2006; 130:1828.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schönhofer B, Köhler D. Effect of non-invasive mechanical ventilation on sleep and nocturnal ventilation in patients with chronic respiratory failure. Thorax 2000; 55:308.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Collard P, Dury M, Delguste P, et al. Movement arousals and sleep-related disordered breathing in adults. Am J Respir Crit Care Med 1996; 154:454.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Masa JF, Celli BR, Riesco JA, et al. Noninvasive positive pressure ventilation and not oxygen may prevent overt ventilatory failure in patients with chest wall diseases. Chest 1997; 112:207.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Annane D, Quera-Salva MA, Lofaso F, et al. Mechanisms underlying effects of nocturnal ventilation on daytime blood gases in neuromuscular diseases. Eur Respir J 1999; 13:157.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Turkington PM, Elliott MW. Rationale for the use of non-invasive ventilation in chronic ventilatory failure. Thorax 2000; 55:417.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Vianello A, Arcaro G, Palmieri A, et al. Survival and quality of life after tracheostomy for acute respiratory failure in patients with amyotrophic lateral sclerosis. J Crit Care 2011; 26:329.e7.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Terzi N, Prigent H, Lejaille M, et al. Impact of tracheostomy on swallowing performance in Duchenne muscular dystrophy. Neuromuscul Disord 2010; 20:493.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Macht M, Wimbish T, Bodine C, Moss M. ICU-acquired swallowing disorders. Crit Care Med 2013; 41:2396.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Finder JD, Birnkrant D, Carl J, et al. Respiratory care of the patient with Duchenne muscular dystrophy: ATS consensus statement. Am J Respir Crit Care Med 2004; 170:456.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rafiq MK, Bradburn M, Proctor AR, et al. A preliminary randomized trial of the mechanical insufflator-exsufflator versus breath-stacking technique in patients with amyotrophic lateral sclerosis. Amyotroph Lateral Scler Frontotemporal Degener 2015; 16:448.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Benditt JO. Respiratory Care of Patients With Neuromuscular Disease. Respir Care 2019; 64:679.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mitropoulou G, Heinzer R, Janssens JP, et al. Home Use of Mechanical Insufflation/Exsufflation in Adult Patients in Western Switzerland. Respiration 2023; 102:341.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bach JR. Update and perspective on noninvasive respiratory muscle aids. Part 2: The expiratory aids. Chest 1994; 105:1538.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sivasothy P, Brown L, Smith IE, Shneerson JM. Effect of manually assisted cough and mechanical insufflation on cough flow of normal subjects, patients with chronic obstructive pulmonary disease (COPD), and patients with respiratory muscle weakness. Thorax 2001; 56:438.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Winck JC, Gonçalves MR, Lourenço C, et al. Effects of mechanical insufflation-exsufflation on respiratory parameters for patients with chronic airway secretion encumbrance. Chest 2004; 126:774.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Andersen TM, Sandnes A, Fondenes O, et al. Laryngeal Responses to Mechanically Assisted Cough in Progressing Amyotrophic Lateral Sclerosis. Respir Care 2018; 63:538.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bach JR, Ishikawa Y, Kim H. Prevention of pulmonary morbidity for patients with Duchenne muscular dystrophy. Chest 1997; 112:1024.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Auger C, Hernando V, Galmiche H. Use of Mechanical Insufflation-Exsufflation Devices for Airway Clearance in Subjects With Neuromuscular Disease. Respir Care 2017; 62:236.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Morrow B, Zampoli M, van Aswegen H, Argent A. Mechanical insufflation-exsufflation for people with neuromuscular disorders. Cochrane Database Syst Rev 2013; :CD010044.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Vianello A, Corrado A, Arcaro G, et al. Mechanical insufflation-exsufflation improves outcomes for neuromuscular disease patients with respiratory tract infections. Am J Phys Med Rehabil 2005; 84:83.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sancho J, Servera E, Vergara P, Marín J. Mechanical insufflation-exsufflation vs. tracheal suctioning via tracheostomy tubes for patients with amyotrophic lateral sclerosis: a pilot study. Am J Phys Med Rehabil 2003; 82:750.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chatwin M, Ross E, Hart N, et al. Cough augmentation with mechanical insufflation/exsufflation in patients with neuromuscular weakness. Eur Respir J 2003; 21:502.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fauroux B, Guillemot N, Aubertin G, et al. Physiologic benefits of mechanical insufflation-exsufflation in children with neuromuscular diseases. Chest 2008; 133:161.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           BARACH AL, BECK GJ. Exsufflation with negative pressure; physiologic and clinical studies in poliomyelitis, bronchial asthma, pulmonary emphysema, and bronchiectasis. AMA Arch Intern Med 1954; 93:825.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bach JR. Mechanical insufflation-exsufflation. Comparison of peak expiratory flows with manually assisted and unassisted coughing techniques. Chest 1993; 104:1553.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bach JR, Saporito LR, Shah HR, Sinquee D. Decanulation of patients with severe respiratory muscle insufficiency: efficacy of mechanical insufflation-exsufflation. J Rehabil Med 2014; 46:1037.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bach JR, Sinquee DM, Saporito LR, Botticello AL. Efficacy of mechanical insufflation-exsufflation in extubating unweanable subjects with restrictive pulmonary disorders. Respir Care 2015; 60:477.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Reid WD, Brown JA, Konnyu KJ, et al. Physiotherapy secretion removal techniques in people with spinal cord injury: a systematic review. J Spinal Cord Med 2010; 33:353.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kang SW, Bach JR. Maximum insufflation capacity: vital capacity and cough flows in neuromuscular disease. Am J Phys Med Rehabil 2000; 79:222.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Katz SL, Barrowman N, Monsour A, et al. Long-Term Effects of Lung Volume Recruitment on Maximal Inspiratory Capacity and Vital Capacity in Duchenne Muscular Dystrophy. Ann Am Thorac Soc 2016; 13:217.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Boitano LJ. Management of airway clearance in neuromuscular disease. Respir Care 2006; 51:913.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           DAIL CW, AFFELDT JE, COLLIER CR. Clinical aspects of glossopharyngeal breathing; report of use by one hundred postpoliomyelitic patients. J Am Med Assoc 1955; 158:445.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bach JR, Bianchi C, Vidigal-Lopes M, et al. Lung inflation by glossopharyngeal breathing and "air stacking" in Duchenne muscular dystrophy. Am J Phys Med Rehabil 2007; 86:295.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kang SW, Bach JR. Maximum insufflation capacity. Chest 2000; 118:61.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           McKim DA, Katz SL, Barrowman N, et al. Lung volume recruitment slows pulmonary function decline in Duchenne muscular dystrophy. Arch Phys Med Rehabil 2012; 93:1117.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Srour N, LeBlanc C, King J, McKim DA. Lung volume recruitment in multiple sclerosis. PLoS One 2013; 8:e56676.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Toussaint M, Pernet K, Steens M, et al. Cough Augmentation in Subjects With Duchenne Muscular Dystrophy: Comparison of Air Stacking via a Resuscitator Bag Versus Mechanical Ventilation. Respir Care 2016; 61:61.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lacombe M, Del Amo Castrillo L, Boré A, et al. Comparison of three cough-augmentation techniques in neuromuscular patients: mechanical insufflation combined with manually assisted cough, insufflation-exsufflation alone and insufflation-exsufflation combined with manually assisted cough. Respiration 2014; 88:215.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lange DJ, Lechtzin N, Davey C, et al. High-frequency chest wall oscillation in ALS: an exploratory randomized, controlled trial. Neurology 2006; 67:991.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sancho J, Servera E, Bañuls P, Marín J. Effectiveness of assisted and unassisted cough capacity in amyotrophic lateral sclerosis patients. Amyotroph Lateral Scler Frontotemporal Degener 2017; 18:498.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Banfi P, Ticozzi N, Lax A, et al. A review of options for treating sialorrhea in amyotrophic lateral sclerosis. Respir Care 2015; 60:446.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sahni AS, Wolfe L. Respiratory Care in Neuromuscular Diseases. Respir Care 2018; 63:601.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Niedermeyer S, Murn M, Choi PJ. Respiratory Failure in Amyotrophic Lateral Sclerosis. Chest 2019; 155:401.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 5124 Version 31.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/36921894" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Respiratory Management of Patients With Neuromuscular Weakness: An American College of Chest Physicians Clinical Practice Guideline and Expert Panel Report.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14694494" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Pulmonary complications of chronic neuromuscular diseases and their management.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7867279" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : An overview of respiratory muscle function.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24378177" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Simple bedside predictors of mechanical ventilation in patients with Guillain-Barre syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31982274" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Serial single breath count is a reliable tool for monitoring respiratory functions in Guillain-BarréSyndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26437790" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Correlation of single-breath count test and neck flexor muscle strength with spirometry in myasthenia gravis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25142771" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Upper airway obstruction during noninvasive ventilation induced by the use of an oronasal mask.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10872129" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Non-invasive ventilatory approach to treatment of acute respiratory failure in neuromuscular disorders. A comparison with endotracheal intubation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16244522" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Alternatives to endotracheal intubation for patients with neuromuscular diseases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12451217" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : BiPAP in acute respiratory failure due to myasthenic crisis may prevent intubation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25406348" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Predictors of need for noninvasive ventilation during respiratory tract infections in medically stable, non-ventilated subjects with amyotrophic lateral sclerosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17019557" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Prognosis and risk factors of early onset pneumonia in ventilated patients with Guillain-Barrésyndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12971736" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Canadian clinical practice guidelines for nutrition support in mechanically ventilated, critically ill adult patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21273033" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Prevention of extubation failure in high-risk patients with neuromuscular disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17290095" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Factors predicting extubation success in patients with Guillain-Barrésyndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16377831" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Risk of extubation failure in patients with myasthenic crisis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22420538" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Effects of mechanical insufflation-exsufflation in preventing respiratory failure after extubation: a randomized controlled trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18625860" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Predictors of extubation failure in myasthenic crisis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12483056" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Ventilatory care in myasthenia gravis crisis: assessing the baseline adverse event rate.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9153452" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Myasthenic crisis: clinical features, mortality, complications, and risk factors for prolonged intubation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10716773" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Post-intubation pulmonary function test in Guillain-Barrésyndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11742959" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Evidence-based guidelines for weaning and discontinuing ventilatory support: a collective task force facilitated by the American College of Chest Physicians; the American Association for Respiratory Care; and the American College of Critical Care Medicine.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16934165" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Neuromuscular disease causing acute respiratory failure.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10881259" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Long-term outcome in patients with Guillain-Barrésyndrome requiring mechanical ventilation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15201647" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Predictive factors and long-term outcome of respiratory failure after Guillain-Barrésyndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23641946" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Diaphragm dysfunction on admission to the intensive care unit. Prevalence, risk factors, and prognostic impact-a prospective study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16174943" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Respiratory dysfunction in Guillain-BarréSyndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8147550" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Noninvasive positive pressure ventilation to treat respiratory failure.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Consensus statement: Noninvasive positive pressure ventilation
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11405803" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Anticipating mechanical ventilation in Guillain-Barrésyndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10227612" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Practice parameter: the care of the patient with amyotrophic lateral sclerosis (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology: ALS Practice Parameters Task Force.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12545029" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Early predictors of mechanical ventilation in Guillain-Barrésyndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1928954" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Repeated vital capacity measurements as predictive parameters for mechanical ventilation need and weaning success in the Guillain-Barrésyndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1552914" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : The Guillain-Barrésyndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8522671" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : The repeated measurement of vital capacity is a poor predictor of the need for mechanical ventilation in myasthenia gravis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29266547" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Impact of an early respiratory care programme with non-invasive ventilation adaptation in patients with amyotrophic lateral sclerosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20957853" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : Best clinical practices for the sleep center adjustment of noninvasive positive pressure ventilation (NPPV) in stable chronic alveolar hypoventilation syndromes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19648521" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : Chronic respiratory care for neuromuscular diseases in adults.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16299118" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : Randomised controlled trial of non-invasive ventilation (NIV) for nocturnal hypoventilation in neuromuscular and chest wall disease patients with daytime normocapnia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16299118" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Randomised controlled trial of non-invasive ventilation (NIV) for nocturnal hypoventilation in neuromuscular and chest wall disease patients with daytime normocapnia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25503955" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : Nocturnal mechanical ventilation for chronic hypoventilation in patients with neuromuscular and chest wall disorders.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11353427" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : Objective measures of the efficacy of noninvasive positive-pressure ventilation in amyotrophic lateral sclerosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9313002" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : Effect of noninvasive positive-pressure ventilation on survival in amyotrophic lateral sclerosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15947331" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : Survival in amyotrophic lateral sclerosis with home mechanical ventilation: the impact of systematic respiratory assessment and bulbar involvement.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10385053" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : Bipap improves survival and rate of pulmonary function decline in patients with ALS.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7595610" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : Respiratory assistance with a non-invasive ventilator (Bipap) in MND/ALS patients: survival rates in a controlled trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16426990" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : Effects of non-invasive ventilation on survival and quality of life in patients with amyotrophic lateral sclerosis: a randomised controlled trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16899545" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : Noninvasive positive-pressure ventilation in ALS: predictors of tolerance and survival.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12114343" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : Amyotrophic lateral sclerosis: prolongation of life by noninvasive respiratory AIDS.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18579546" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : Impact of home mechanical ventilation on health-related quality of life.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20588002" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : Noninvasive ventilation in chronic respiratory failure: effects on quality of life.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24315469" id="rid51" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          52 : Systematic review of non-invasive positive pressure ventilation for chronic respiratory failure.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8915217" id="rid52" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          53 : Long-term effects of nasal intermittent positive-pressure ventilation on pulmonary function and sleep architecture in patients with neuromuscular diseases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26234554" id="rid53" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          54 : Safety and efficacy of diaphragm pacing in patients with respiratory insufficiency due to amyotrophic lateral sclerosis (DiPALS): a multicentre, open-label, randomised controlled trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27751553" id="rid54" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          55 : Early diaphragm pacing in patients with amyotrophic lateral sclerosis (RespiStimALS): a randomised controlled triple-blind trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17167004" id="rid55" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          56 : Survival of patients with kyphoscoliosis receiving mechanical ventilation or oxygen at home.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10722771" id="rid56" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          57 : Effect of non-invasive mechanical ventilation on sleep and nocturnal ventilation in patients with chronic respiratory failure.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8756822" id="rid57" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          58 : Movement arousals and sleep-related disordered breathing in adults.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9228378" id="rid58" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          59 : Noninvasive positive pressure ventilation and not oxygen may prevent overt ventilatory failure in patients with chest wall diseases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10836341" id="rid59" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          60 : Mechanisms underlying effects of nocturnal ventilation on daytime blood gases in neuromuscular diseases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10770824" id="rid60" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          61 : Rationale for the use of non-invasive ventilation in chronic ventilatory failure.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20655697" id="rid61" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          62 : Survival and quality of life after tracheostomy for acute respiratory failure in patients with amyotrophic lateral sclerosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20558065" id="rid62" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          63 : Impact of tracheostomy on swallowing performance in Duchenne muscular dystrophy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23939361" id="rid63" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          64 : ICU-acquired swallowing disorders.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15302625" id="rid64" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          65 : Respiratory care of the patient with Duchenne muscular dystrophy: ATS consensus statement.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26140500" id="rid65" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          66 : A preliminary randomized trial of the mechanical insufflator-exsufflator versus breath-stacking technique in patients with amyotrophic lateral sclerosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31110036" id="rid66" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          67 : Respiratory Care of Patients With Neuromuscular Disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/36724753" id="rid67" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          68 : Home Use of Mechanical Insufflation/Exsufflation in Adult Patients in Western Switzerland.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8181348" id="rid68" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          69 : Update and perspective on noninvasive respiratory muscle aids. Part 2: The expiratory aids.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11359958" id="rid69" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          70 : Effect of manually assisted cough and mechanical insufflation on cough flow of normal subjects, patients with chronic obstructive pulmonary disease (COPD), and patients with respiratory muscle weakness.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15364756" id="rid70" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          71 : Effects of mechanical insufflation-exsufflation on respiratory parameters for patients with chronic airway secretion encumbrance.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29666294" id="rid71" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          72 : Laryngeal Responses to Mechanically Assisted Cough in Progressing Amyotrophic Lateral Sclerosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9377912" id="rid72" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          73 : Prevention of pulmonary morbidity for patients with Duchenne muscular dystrophy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28108686" id="rid73" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          74 : Use of Mechanical Insufflation-Exsufflation Devices for Airway Clearance in Subjects With Neuromuscular Disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24374746" id="rid74" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          75 : Mechanical insufflation-exsufflation for people with neuromuscular disorders.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15668554" id="rid75" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          76 : Mechanical insufflation-exsufflation improves outcomes for neuromuscular disease patients with respiratory tract infections.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14508404" id="rid76" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          77 : Mechanical insufflation-exsufflation vs. tracheal suctioning via tracheostomy tubes for patients with amyotrophic lateral sclerosis: a pilot study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12662009" id="rid77" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          78 : Cough augmentation with mechanical insufflation/exsufflation in patients with neuromuscular weakness.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18071020" id="rid78" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          79 : Physiologic benefits of mechanical insufflation-exsufflation in children with neuromuscular diseases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/13157670" id="rid79" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          80 : Exsufflation with negative pressure; physiologic and clinical studies in poliomyelitis, bronchial asthma, pulmonary emphysema, and bronchiectasis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8222823" id="rid80" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          81 : Mechanical insufflation-exsufflation. Comparison of peak expiratory flows with manually assisted and unassisted coughing techniques.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25096928" id="rid81" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          82 : Decanulation of patients with severe respiratory muscle insufficiency: efficacy of mechanical insufflation-exsufflation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25492956" id="rid82" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          83 : Efficacy of mechanical insufflation-exsufflation in extubating unweanable subjects with restrictive pulmonary disorders.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21061895" id="rid83" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          84 : Physiotherapy secretion removal techniques in people with spinal cord injury: a systematic review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10821306" id="rid84" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          85 : Maximum insufflation capacity: vital capacity and cough flows in neuromuscular disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26599476" id="rid85" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          86 : Long-Term Effects of Lung Volume Recruitment on Maximal Inspiratory Capacity and Vital Capacity in Duchenne Muscular Dystrophy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16867201" id="rid86" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          87 : Management of airway clearance in neuromuscular disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14381189" id="rid87" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          88 : Clinical aspects of glossopharyngeal breathing; report of use by one hundred postpoliomyelitic patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17413542" id="rid88" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          89 : Lung inflation by glossopharyngeal breathing and "air stacking" in Duchenne muscular dystrophy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10893360" id="rid89" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          90 : Maximum insufflation capacity.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22421625" id="rid90" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          91 : Lung volume recruitment slows pulmonary function decline in Duchenne muscular dystrophy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23383293" id="rid91" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          92 : Lung volume recruitment in multiple sclerosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26443018" id="rid92" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          93 : Cough Augmentation in Subjects With Duchenne Muscular Dystrophy: Comparison of Air Stacking via a Resuscitator Bag Versus Mechanical Ventilation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25171575" id="rid93" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          94 : Comparison of three cough-augmentation techniques in neuromuscular patients: mechanical insufflation combined with manually assisted cough, insufflation-exsufflation alone and insufflation-exsufflation combined with manually assisted cough.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17000967" id="rid94" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          95 : High-frequency chest wall oscillation in ALS: an exploratory randomized, controlled trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28597697" id="rid95" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          96 : Effectiveness of assisted and unassisted cough capacity in amyotrophic lateral sclerosis patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25228780" id="rid96" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          97 : A review of options for treating sialorrhea in amyotrophic lateral sclerosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29692352" id="rid97" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          98 : Respiratory Care in Neuromuscular Diseases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29990478" id="rid98" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          99 : Respiratory Failure in Amyotrophic Lateral Sclerosis.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
